Recruiting

Beta Blocker

Sponsor:

David Lanfear

Code:

NCT07054489

Conditions

Heart Failure

Polygenic Score

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Beta blocker

Study Details

Brief summary:

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Conditions

Heart Failure

Polygenic Score

Study ID

NCT07054489

Start date

Mar 30, 2026

Status verified date

May, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18-89 years
  • Ejection Fraction (EF) >40% and =<50% by any modality within 1 year (must be most recent)
  • Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP>35 ng/L or NTproBNP >125 ng/L at any time
  • Expected ability to fully participate in study (can tolerate study processes, no long travel)

Exclusion Criteria:

  • Unable to provide informed consent
  • Previous documented EF =< 35%
  • Currently on BB =>25% target dose
  • Uncontrolled hypertension (systolic BP > 180 at enrollment)
  • Has contraindications to all BB or intolerance to metoprolol
  • Systolic BP < 100 or heart rate <70
  • Current cancer requiring active treatment
  • Heart transplant or LVAD or expected in the next year
  • Life expectancy < 1 year for any reason
  • Dialysis dependence or ESRD
  • MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future
  • Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
  • If PI decides for any reason participation in trial is not in best interest of the patient
  • Has a contraindication to completing MRI procedures

Study Design

Enrollment

10 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Beta Blocker

This group will be dispensed and titrated on beta blocker according to study protocol.

no intervention: Placebo

This group will be dispensed and titrated on placebo according to study protocol.

Interventions

Beta blocker

Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.

Primary outcome measure

  • Change in left ventricle end systolic volume index [ Time Frame: Within 6 months of randomization ]

Central Contacts and Locations

Central contacts

Whitney Cabral, MS

313-949-6616wcabral1@hfhs.org

Locations

Henry Ford Health

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Whitney Cabral

313-949-6616WCABRAL1@hfhs.org

More Information

Sponsor

David Lanfear

Last update posted

Jul 7, 2026

Last verified

May, 2026

Keywords

  • Beta blocker
  • Metoprolol

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by David Lanfear on 2026-07-07.